Marked for death: targeting epigenetic changes in cancer.

Area of Science:

• Oncology
• Epigenetics
• Drug Discovery

Background:

• Mutations in epigenetic regulatory genes are frequently observed in human cancers.
• Targeting these mutations with chemical inhibitors is a developing therapeutic strategy.
• Synthetic lethality offers a novel approach for cancers resistant to conventional treatments.

Purpose of the Study:

• To review recent advancements in epigenetic drug discovery and development for cancer treatment.
• To explore future research directions in the field of epigenetic therapies.

Main Methods:

• Review of current literature on epigenetic drug discovery.
• Analysis of clinical trial data for epigenetic therapies.
• Discussion of synthetic lethality principles in cancer treatment.

Main Results:

• Epigenetic drug discovery is rapidly advancing with several promising chemical inhibitors.
• Synthetic lethality approaches are gaining traction and entering clinical trials.
• Clinical trials are actively evaluating the efficacy of these novel cancer therapies.

Conclusions:

• Epigenetic therapies, including chemical inhibitors and synthetic lethality, represent a significant frontier in cancer treatment.
• Continued research and development are crucial for realizing the full potential of epigenetic drugs.
• Future investigations should focus on optimizing drug delivery and identifying new epigenetic targets.